| ￥3500 | |
| Z04846-100 | |
|
|
|
|
|
|
|
|
|
| Species | Cynomolgus | ||||
| Protein Construction |
|
||||
| Purity | > 95% as determined by BisTris PAGE | ||||
| Endotoxin Level | Less than 1EU per μg by the LAL method. | ||||
| Biological Activity | Measured by its binding ability in a functional ELISA.Test result was comparable to standard batch. | ||||
| Expression System | HEK293 | ||||
| Theoretical Molecular Weight | 22.06 kDa | ||||
| Apparent Molecular Weight | Due to glycosylation, the protein migrates to 25-30 kDa based on Bis-Tris PAGE result. | ||||
| Formulation | Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). | ||||
| Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. | ||||
| Storage & Stability | Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles. |
Loaded IL-6, His, Cynomolgus, hFc Tag on ProA-Biosensor can bind Cynomolgus IL-6, His Tag with an affinity constant of 21.60 nM as determined in BLI assay (Gator® Prime). »
Immobilized IL-6, His, Cynomolgus, His Tag at 5 μg/ml(100 μl/well) on the plate. Dose response curve for Human IL-6 R alpha, hFc Tag with the EC50 of 6.6ng/ml determined by ELISA. »
The purity of IL-6, His, Cynomolgus is greater than 95% as determined by SEC-HPLC. »
IL-6, His, Cynomolgus on Bis-Tris PAGE under reduced condition. The purity is greater than 95%. »
| Target Background | IL-6 (Interleukin-6) is a pleiotropic cytokine that acts in the acute phase reaction, inflammation, hematopoiesis, bone metabolism, and cancer progression.Interleukin 6 has been shown to interact with interleukin-6 receptor and glycoprotein. |
| Synonyms | IFN-beta-2; IL6; IL-6; BSF-2; CDF; MGI-2A; Interleukin-6; HSF; IFNB2; HGF;IFN-β-2 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
